Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Charles River Laboratories (CRL) - CRL currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a favorable outlook for the stock [3][4] - The stock has shown significant price performance, with a 9.13% increase over the past week and a 10.41% increase over the past month, outperforming the Zacks Medical Services industry, which rose 2.52% and 1.48% respectively [6] - Over the past quarter, CRL shares increased by 15.72%, and over the last year, they gained 24.43%, compared to the S&P 500's increases of 4.57% and 19.92% [7] Trading Volume - CRL's average 20-day trading volume is 605,064 shares, which serves as a baseline for price-to-volume analysis; a rising stock with above-average volume is generally seen as bullish [8] Earnings Outlook - Recent earnings estimate revisions for CRL have been positive, with 2 estimates moving higher for the current fiscal year, raising the consensus estimate from $10.21 to $10.22 [10] - For the next fiscal year, 3 estimates have increased with no downward revisions, indicating a positive trend in earnings expectations [10] Conclusion - Given the positive momentum indicators and earnings outlook, CRL is positioned as a strong buy candidate for investors seeking short-term gains [12]